Janus kinase inhibitors in autoimmune diseases

John J. O'Shea, Apostolos Kontzias, Kunihiro Yamaoka, Yoshiya Tanaka, Arian Laurence

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to consider this new category of drugs and reflect on their potential roles, present and future, in the treatment of RA and related disorders.

Original languageEnglish
Pages (from-to)ii111-ii115
JournalAnnals of the rheumatic diseases
Volume72
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2013 Apr 1

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

O'Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013). Janus kinase inhibitors in autoimmune diseases. Annals of the rheumatic diseases, 72(SUPPL. 2), ii111-ii115. https://doi.org/10.1136/annrheumdis-2012-202576